Skip to content
Screener

Recursion Pharmaceuticals, Inc. RXRX Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Schrodinger logo
SchrodingerSDGR
$939K+590%
Absci Corporation logo
Absci CorporationABSI
$1.31M-11.9%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$9.71M+523%
Septerna, Inc. logo
Septerna, Inc.SEPN
$521K+25,950%
Xencor logo
XencorXNCR
$152K
Regenxbio logo
RegenxbioRGNX
$486K-26.8%

Other financials

Income statement

See full
Revenue$7.7M-60.1%
Gross profit-$3.8M-307%
Operating income-$135.0M+23.4%
Net income-$131.0M+23.8%
EPS (diluted)-$0.25+39.0%

Balance sheet

See full
Cash & equivalents$556.8M+4.3%
Total debt$80.5M-27.2%
Total equity$915.0M-0.5%
Total assets$1.2B-6.9%

Cash flow

See full
Operating cash flow-$105.9M-38.6%
CapEx$44.0K-98.6%
Free cash flow-$106.0M-33.2%

Valuation

See full
Market cap$1.73B-24.8%
Enterprise value$1.25B-33.3%
P/S31.5×-4.1×

Profitability

See full
Gross margin3.5%
Operating margin-991.7%-13.7pp
Net margin-945.9%-52.4pp
FCF margin-642.2%+36.1pp

Returns & leverage

See full
Return on equity-56.6%-14.5pp
Debt / equity0.1×0.0×
Current ratio+1.5×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 6:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001601830-26-000098
Line itemJune 30, 2026December 31, 2025
Operating lease liabilities, non-current39,19346,647
Notes payable and financing lease liabilities, non-current4,7539,564
Deferred tax liabilities18,31323,255
Other liabilities, non-current2,7022,080
Total liabilities297,665343,265
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2026 and December 31, 2025; 534,120,235 shares (Class A 533,191,318, Class B — and Exchangeable 928,917) and 528,182,693 shares (Class A 521,831,046, Class B 5,547,334 and Exchangeable 804,313) issued and outstanding as of June 30, 2026 and December 31, 2025, respectively55

Item 1. Financial Statements (unaudited)

FAQ

What is Recursion Pharmaceuticals, Inc.'s other non-current liabilities?
Recursion Pharmaceuticals, Inc. (RXRX) reported other non-current liabilities of $2.7M in Q2 2026.
How has Recursion Pharmaceuticals, Inc.'s other non-current liabilities changed year-over-year?
Recursion Pharmaceuticals, Inc.'s other non-current liabilities increased by 72.7% year-over-year, from $1.57M to $2.7M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Recursion Pharmaceuticals, Inc.'s other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude